Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.780
+0.040 (2.30%)
At close: Sep 14, 2026, 4:00 PM EDT
1.790
+0.010 (0.56%)
After-hours: Sep 14, 2026, 7:45 PM EDT
Biomea Fusion Employees
Biomea Fusion had 37 employees as of June 30, 2026. The number of employees decreased by 26 or -41.27% compared to the same quarter last year.
Employees
37
Change
-26
Growth
-41.27%
Revenue / Employee
n/a
Profits / Employee
-$879,405
Market Cap
129.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 37 | -26 | -41.27% |
| Mar 31, 2026 | 40 | -39 | -49.37% |
| Dec 31, 2025 | 41 | -65 | -61.32% |
| Sep 30, 2025 | 42 | -65 | -60.75% |
| Jun 30, 2025 | 63 | -49 | -43.75% |
| Mar 31, 2025 | 79 | -31 | -28.18% |
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Sep 30, 2024 | 107 | 4 | 3.88% |
| Jun 30, 2024 | 112 | 18 | 19.15% |
| Mar 31, 2024 | 110 | 24 | 27.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Sep 30, 2023 | 103 | 28 | 37.33% |
| Jun 30, 2023 | 94 | 22 | 30.56% |
| Mar 31, 2023 | 86 | 29 | 50.88% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Sep 30, 2022 | 75 | 28 | 59.57% |
| Jun 30, 2022 | 72 | 52 | 260.00% |
| Mar 31, 2022 | 57 | 37 | 185.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Nautilus Biotechnology | 127 |
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| enGene Therapeutics | 82 |
| Connect Biopharma Holdings | 64 |
| OnKure Therapeutics | 45 |
| TuHURA Biosciences | 22 |
| Equillium | 15 |
BMEA News
- 11 days ago - Biomea Fusion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Biomea Fusion completes enrollment in COVALENT-211 trial - TheFly
- 21 days ago - Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes - GlobeNewsWire
- 21 days ago - Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - Invezz
- 4 weeks ago - Biomea Fusion doses first patient in OPAL study - TheFly
- 4 weeks ago - Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - GlobeNewsWire
- 4 weeks ago - Citi adds ‘upside 90-day catalyst watch’ on Biomea into GLP-1 data - TheFly
- 5 weeks ago - Biomea Fusion price target lowered to $7 from $9 at Citizens - TheFly